Latest quarter
Healthpeak reported Q3 FY2026 revenue of $820.9 million, above the consensus estimate of $758.3 million. Adjusted EPS, as counted by the consensus, was $0.44, compared with the $0.43 estimate.
Revenue rose 16.3% from $705.9 million a year earlier. Diluted EPS was $0.02, compared with −$0.17 in Q3 FY2025. The filing attributed the increase in net income applicable to common shares in part to lower impairment charges and higher adjusted net operating income from senior housing and lab properties.
In senior housing, the company cited acquisitions, higher occupancy and increased resident fees. Lab income benefited from acquisitions, projects placed in service and new leasing, partly offset by dispositions and lower occupancy. Outpatient medical adjusted property income declined, with the filing citing dispositions and lower occupancy among the factors.
Healthpeak’s gross margin was 53.8%, compared with 58.6% a year earlier. Free cash flow was $354.5 million, up from $111.6 million.
| Q3 FY2026 | Q3 FY2025 | Change | |
|---|---|---|---|
| Revenue | $820.9 million | $705.9 million | 16.3% |
| Diluted EPS | $0.02 | −$0.17 | — |
| Gross margin | 53.8% | 58.6% | −4.9 percentage points |
| Operating margin | 15.2% | 16.7% | −1.5 percentage points |
| Free cash flow | $354.5 million | $111.6 million | 217.5% |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $0.44 | $0.43 | Beat by 2.33% |
| Revenue | $820.9 million | $758.3 million | Beat by 8.26% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
CEO Scott Brinker said demand for outpatient care is being driven by an aging population and health systems’ efforts to manage costs. CFO Kelvin said outpatient leasing included new leases and renewals, with positive net absorption during the quarter. Brinker expects internal growth in the business to accelerate in 2027, citing recent leases and the pipeline.
In labs, Kelvin said occupancy increased during the quarter as Healthpeak signed leases, and he expects those leases to support future property income as tenants move in and begin paying rent. Brinker cautioned that build-outs mean it takes time for executed leases to produce rental income. He said the company’s reported occupancy will reset lower when its newly announced acquisitions close because the properties have vacant space.
Brinker said the acquired life science buildings are surrounded by Healthpeak’s existing properties and that its tenant relationships can help fill them. On the acquisition environment, he said: “Capital availability in this sector has gone from overly abundant to severely constrained.” Asked about the strategy, he said Healthpeak is concentrating on markets where it already has a presence rather than entering new submarkets.
Chief Development Officer Scott Bohn said biotech tenants still account for most of the lab pipeline, while demand from artificial intelligence and robotics users is increasing. Asked about regional pricing, Bohn said Boston faces the greatest pressure on deal economics because of the imbalance between supply and demand; he said individual lease economics depend on the tenant, space, capital and term.
Kelvin said Healthpeak has $1.4 billion of debt maturing in 2027 and expects to draw $400.0 million and $500.0 million delayed-draw loans to reduce commercial paper balances. He said the maturing debt carries a borrowing cost of around 3.00%, below current market rates, and that it was too early to specify the long-term financing tools Healthpeak would use.
Guidance
Healthpeak raised its FY2026 adjusted funds from operations guidance to $1.76 to $1.78 per share from its previous range. Kelvin said the update reflects leasing across the portfolio and the delayed timing of remaining dispositions.
The company also raised its total same-store cash net operating income growth outlook to 0.50% to 2.00%. Its updated segment outlook calls for outpatient medical growth of 2.50% to 3.00%, a lab decline of 6.00% to 3.00%, and senior housing growth of 16.0% to 19.0%.
| Metric | For | Guide | Previous guide | Change |
|---|---|---|---|---|
| Capex | FY2027 | Healthpeak expects FY2027 capex to be consistent with past years. | — | — |
| Operating income growth, Non Gaap Senior Housing Same Store Cash Noi | FY2026 | 16.0%–19.0% | — | New |
| Operating income growth, Non Gaap Lab Same Store Cash Noi | FY2026 | −6.00%–−3.00% | — | New |
| Operating income growth, Non Gaap Outpatient Medical Same Store Cash Noi | FY2026 | 2.50%–3.00% | — | New |
| Operating income growth, Non Gaap Same Store Cash Noi | FY2026 | 0.50%–2.00% | — | New |
| EPS, Non Gaap Ffo Per Share | FY2026 | $1.76–$1.78 | — | New |
| EPS | FY2026 | $1.71–$1.75 | — | New |